logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical Medical says it is moving towards proof of concept with its blue scorpion venom research

Venom from the Caribbean blue scorpion has been shown to impact aggressive cancers, such as in the brain

PreveCeutical Medical Inc -
PreveCeutical said it was now "accelerating the process of evaluating options" on how best to progress two lead peptide drug candidates

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) revealed it has advanced its scorpion venom-derived research and development (R&D) program toward proof of concept studies.

The health sciences group, which is developing innovative preventive therapies using organic and nature identical products, noted that venom from the Caribbean blue scorpion has been shown to impact aggressive cancers, such as in the brain.

READ: PreveCeutical completes efficacy screening of small interfering RNA-based therapy for type 2 diabetes

The firm said its research partner, via work, has whittled down four peptides to two which show the most potential for further development as therapeutic agents in the management of certain brain cancers.

The two peptides were "able to inhibit the activity of the target protein", which resulted in an obvious slowing of invasion, particularly in cancer cells, the company added.

They also displayed modest suppression of an important cancer cell marker, which has a role in promoting cancer spread/metastasis and is also associated with drug and immune resistance in brain cancer, the Vancouver-based firm said.

Accelerating the process

PreveCeutical said it was now "accelerating the process of evaluating options on how best to progress the two lead peptide drug candidates", which may include partnering to speed up pre-clinical evaluation.

"The pre-clinical outcomes, along with the company's IP coverage, would have the potential to demonstrate proof of concept and enable the company to further extend dialogue with pharma R & D / biotech companies active in the therapeutic neuro-oncology space," it noted.

"We are indeed quite excited to have accomplished further strides towards proof of concept for these innovative Nature Identical peptide therapeutics for application into the neuro-oncology therapeutic area and look forward to progressing them through proof of concept studies," said PreveCeutical's president and chief science officer Dr Mak Jawadekar.

Shares surged 20% in Toronto to C$0.030 each.

Contact the author at [email protected]

Quick facts: PreveCeutical Medical Inc.

Price: 0.02 CAD

CSE:PREV
Market: CSE
Market Cap: $7.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

PreveCeutical Medical making key advances with its Sol-gel program

Dr Harry Parekh, chief research officer for PreveCeutical Medical Inc (CSE: PREV, OTCQB: PRVCF), tells Proactive's Andrew Scott they've hit a number of key milestones with their Sol-gel program. He says they've now successfully optimised the conditions for extracting cannabinoids from one...

on 10/9/18

2 min read